Please login to the form below

Not currently logged in
Email:
Password:

veliparib

This page shows the latest veliparib news and features for those working in and with pharma, biotech and healthcare.

GSK’s Zejula challenges AZ/Merck’s Lynparza in PARP inhibitor category

GSK’s Zejula challenges AZ/Merck’s Lynparza in PARP inhibitor category

Also looking to carve a piece of the PARP inhibitor market in ovarian cancer is AbbVie, who also revealed positive data in this therapy area with its candidate veliparib.

Latest news

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....